Member access

4-Traders Homepage  >  Shares  >  Toronto Stock Exchange  >  Cardiome Pharma Corp.    COM   CA14159U3010

SummaryChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Business Summary
Engages in the discovery, development and commercialization of new therapies

Cardiome Pharma Corp. is a specialty pharmaceutical company, which engages in the discovery, development and commercialization of cardiovascular therapies that will improve the health of patients suffering from heart disease.

Cardiome has two marketed, in-hospital, cardiology products, BRINAVESS, approved in Europe and other territories for the rapid conversion of recent onset atrial fibrillation to sinus rhythm in adults, and AGGRASTAT a reversible GP IIb/IIIa inhibitor indicated for use in patients with acute coronary syndrome.

The company was founded on December 12, 1986 and is headquartered in Vancouver, Canada.

Number of employees : 85 persons.
Sales per Businesses
20132014Delta
CAD (in Million)%CAD (in Million)%
Cardiovascular Therapies4.67100.5%33.21100.1% +85.93%
Sales per Regions
20132014Delta
CAD (in Million)%CAD (in Million)%
Rest of World2.7158.2%17.3952.4% +84.44%
Europe1.9642.3%15.8247.7% +87.58%
Managers
NameAgeSinceTitle
William L. Hunter, MD522007President, Chief Executive Officer & Director
Robert W. Rieder, MBA691997Non-Executive Chairman
Sheila M. Grant, MBA-2003Chief Operating Officer
Jennifer Archibald, CA-2006Chief Financial Officer
Harold H. Shlevin, PhD652004Independent Director
Peter W. Roberts, CPA712005Independent Director
William James O'Shea652014Independent Director
Richard M. Glickman, PhD552006Lead Independent Director
Jürgen Polifka, PhD-2013General Manager-European Sales & Marketing
Karim F. Lalji-2006Chief Commercial Officer
Shareholders
NameShares%
Westfield Capital Management Co. LP 2,236,577 13.3%
Fidelity Management & Research Co. 1,595,312 9.51%
Putnam Investment Management LLC 1,400,834 8.35%
Clough Capital Partners LP 597,183 3.56%
Rock Springs Capital Management LP 565,000 3.37%
William L. Hunter, MD 510,000 3.04%
Adage Capital Management LP 500,000 2.98%
AlphaOne Investment Services LLC 312,684 1.86%
PointState Capital LP 312,437 1.86%
Turner Investments LP 311,463 1.86%
Sector
Healthcare
Pharmaceuticals & Medical Research
 Pharmaceuticals
  Pharmaceuticals
   Biopharmaceuticals
Advertisement
Sector Pharmaceuticals
Growth (Revenue) Profitability
GILEAD SCIENCES, ..
AMGEN, INC.
ABBVIE INC
BIOGEN INC
CELGENE CORPORATI..
ASTRAZENECA PLC
ALEXION PHARMACEU..
VERTEX PHARMACEUT..
UCB
GRIFOLS SA
JAZZ PHARMACEUTIC..
INDIVIOR PLC
CHONGQING ZHIFEI ..
-
CELLDEX THERAPEUT..
WALVAX BIOTECHNOL..
-
MEDY TOX INC
STAIDSON (BEIJING..
GREEN CROSS CORP
AMAG PHARMACEUTIC..
THERAVANCE INC
Sector Pharmaceuticals
Cardiome Pharma Corp. : Connections
ESSA Pharmaceuticals Inc
Canadian Public Accountability Board
BC Advantage Funds (VCC) Ltd.
Michael Smith Foundation for Health Research
Nventa Biopharmaceuticals Corp.
Canadian Institute of Chartered Accountants
Xortx Pharma Corp.
Kearny Venture Partners
Richardson Capital Ltd.
ATDC Seed Capital Fund LLC
Premier's Technology Council
Institute of Corporate Directors
MedGenesis Therapeutix, Inc.
Trevi Therapeutics, Inc.
The Institute of Electrical & Electronics Engineers, Inc.
ProStrakan Group Plc
Licensing Executives Society
enGene, Inc.
The American Physiological Society
viDA Therapeutics, Inc.
American Society for Pharmacology & Experimental Therapeutic
Beth Israel Deaconess Medical Center, Inc.
Company contact information
Cardiome Pharma Corp.
6190 Agronomy Road
Suite 405
Vancouver, BC V6T 1Z3

Phone : +1.604.677.6905
Fax : +1.604.677.6915
Web : www.cardiome.com
© 2015 People , Fundamentals and Ownership